贝那普利联合阿托伐他汀治疗慢性心力衰竭的临床疗效  

Effect of Benazepril and Atorvastatin on Treatment of Chronic Heart Failure

作　　者：方玲[1] 李冠兰[1] 李云[1] 潘展群[1] 钟金鹏[1] FANG Ling LI Guan-lan LI Yun PAN Zhan-qun ZHONG Jin-peng(Department of Cardiology, people＇s Hospital of China Three Gorges University, Yichang, Hubei, 443000, Chin)

机构地区：[1]三峡大学人民医院心内科,湖北宜昌443000

出　　处：《现代生物医学进展》2017年第11期2102-2105,共4页Progress in Modern Biomedicine

基　　金：湖北省自然科学基金项目(2006ABA23)

摘　　要：目的:探讨贝那普利联合阿托伐他汀治疗慢性心力衰竭临床疗效及对患者血清炎症因子水平的影响。方法:收集我院2014年12月~2016年5月确诊为慢性心力衰竭的患者120例,随机分为观察组和对照组,各60例。对照组采用口服贝那普利治疗,观察组采用贝那普利联合阿托伐他汀治疗。观察并比较两组患者治疗前后左室收缩末期容积指数(LVESVI)、左室舒张末期容积指数(LVEDVI)、左心室舒张末期内径(LVEDD)、左心射血分数(LVEF)及血清NT-proBNP,hs-CRP,TNF-α,白介素-6(IL-6)及白介素-8(IL-8)水平的变化情况。结果:观察组有效率优于对照组,差异具有统计学意义(P<0.05);治疗后,两组患者Pro-BNP、LVEDD、E/A均降低,且观察组低于对照组(P<0.05);治疗后,两组患者LVEF升高,且观察组高于对照组(P<0.05);两组患者治疗后血清hs-CRP,TNF-α,IL-6及IL-8水平均降低,且观察组低于对照组(P<0.05)。结论:贝那普利联合阿托伐他汀治疗对慢性心力衰竭患者进行治疗,疗效显著,患者炎症反应小,是一种安全有效的治疗方法。Objective： To explore the clinical effects of benazepril and Atorvastatin on the treatment of chronic heart failure and the serum levels of inflammatory factors. Methods： 120 cases with chronic heart failure who were treated in our hospital from December 2014 to May 2016 were selected and randomly divided into the observation group and the control group, with 41 cases in each group. The patients in the control group were treated with benazepril, while the patients in the observation group were treated with benazepril and atorvastatin. Then the changes of the ventricular end-systolic volume index （LVESVI）, the left ventrieular end-diastolic volume index （LVEDVI）, the left ventricular end diastolic diameter （LVEDD） the left ventricular ejection fraction （LVEF）, and the serum levels of NT-proBNP, hs-CRP, TNF-α, IL-6 and IL-8 in the two groups were observed and compared before and after the treatment. Rosults： The effective rate of the observation group was obviously higher than that of the control group （P〈0.05）; After treatment, the levels of Pro-BNP, LVEDD and E/A were significantly decreased in the two groups, and the observation group was lower than that of the control group （P〈0.05）; After treatment, the LVEF was significantly increased in two groups, and the observation group was higher than that of the control group （P〈0.05）. After treatment, the serum levels of hs-CRP, TNF-α, 1I,-6 and IL-8 in the two groups were significantly de- creased, and the observation group was lower than that of the control group （P〈0.05）. Conclusions： Benazepril and Atorvastatin have ob- vious clini- cal effects on the treatment of chronic heart failure, which can reduce the levels of the inflammatory factors and it is safe for clinical application.

关 键 词：慢性心力衰竭 贝那普利 阿托伐他汀 炎症因子 

分 类 号：R541.61[医药卫生—心血管疾病]